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ABSTRACT
Background: Second-line treatment for advanced non-small-cell lung cancer 
(NSCLC) patients includes monotherapy with a third-generation cytotoxic drug (CT) 
or a tyrosine kinase inhibitor (TKI). These options are the actual standard for EGFR 
wild-type (WT) status, as patients with EGFR mutations achieve greater benefit by the 
use of TKI in first-line treatment. Some clinical trials and meta-analyses investigated 
the comparison between CT and TKI in second-line, but data are conflicting.
Methods: We designed a retrospective trial to gather information about TKI 
sensitivity in comparison with CT. We selected from clinical records patients treated 
with at least 1 line of CT and at least 1 line of TKI. We collected data about age, sex, 
performance status, comorbidity, smoking status, histotype, metastatic sites, EGFR 
status, treatment schedule, better response and time-to-progression (TTP) for each 
line of treatment and overall survival (OS).
Results: 93 patients met selection criteria. Mean age 66,7 (range: 46–84). M/F 
ratio is 3:1. 39 EGFR-WT and 54 EGFR-UK. All patients received erlotinib or gefitinib 
as second-line treatment or erlotinib as third-line treatment. No TTP differences 
were observed for both second-line (HR:0,91; p = 0,6333) and third-line (HR:1.1; 
p = 0,6951) treatment (TKI vs CT). A trend of a benefit in OS in favor of 3rd-line TKI 
(HR:0,68; p = 0,11).
Conclusions: This study explores the role of TKIs in EGFR non-mutated NSCLC 
patients. OS analysis highlights a trend to a benefit in patients who received TKI in 
third-line, even if this result is statistically non-significant. Further analysis are needed 
to find an explanation for this observation.
INTRODUCTION
In the last few years we have witnessed a rapid 
evolution and expansion of systemic anti-cancer treatments 
available for patients with advanced non-small-cell 
 lung cancer (NSCLC), whose prognosis has been very 
poor, with 1−, 2−, and 5-years survival rates of 19%, 
8%, and 4%, respectively. Targeted therapy became the 
new standard of care in a subgroup of patients selected 
according to their tumor molecular profile. Both epidermal 
growth factor receptor (EGFR) and EML4-ALK tyrosine 
kinase inhibitors (TKI) are currently recommended as the 
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best treatment option for patients whose tumors harbor 
EGFR sensitizing mutations or EML4-ALK translocations, 
respectively, resulting in a significant improvement of 
survival outcomes, which nearly doubled compared to 
standard chemotherapy [1–4].
For the majority of NSCLC patients without a 
targetable oncogene driver, platinum-based combinations, 
including gemcitabine and pemetrexed/bevacizumab, 
for squamous and non-squamous histology, respectively, 
represent still the backbone. The advent of the continuum 
maintenance strategy with pemetrexed or bevacizumab 
has further improved the survival outcomes of patients 
with adenocarcinoma histology, reaching a new plateau 
of about 14–16 months [5–7], while fewer options remain 
available for patients with squamous cell lung cancer. 
Unfortunately all NSCLC patients develop acquired 
resistance within 6–10 months of  treatment, with only 
20% and 8% of all diagnosed population being able to 
tolerate second- and third-line therapy, respectively [8].
After several years of research, new drugs have 
recently emerged as effective therapeutic options also 
in pre-treated patients who have been characterized  by 
a particular poor prognosis and limited survival. The 
addition of the anti-angiogenic agents Nintedanib or 
Ramucirumab to docetaxel has shown a modest but 
significant survival benefit in patients who progressed to 
first-line platinum-based chemotherapy [9–14], leading 
to the approval of both drugs in this setting of patients. 
Immunotherapy, including anti-PD1 and anti-PD-L1 
monoclonal antibodies (MoAbs), represents another 
promising strategy, which shows a significant superiority 
compared to standard chemotherapy in pre-treated NSCLC 
patients [15–17], while ongoing studies are exploring its 
potential application also in first-line setting.
However we are still far from their introduction into 
clinical practice. Therefore the current treatment options 
available in second-line treatment include docetaxel, 
pemetrexed, and the EGFR-TKI erlotinib, which is the only 
one approved also as third-line therapy, as highlighted by the 
BR.21 study, first showing a clinical benefit of erlotinib over 
placebo in a pre-treated and unselected NSCLC population 
[18]. After this trial several studies included in two recent 
meta-analyses compared erlotinib to standard second-
line chemotherapy, such as docetaxel and pemetrexed, 
showing conflicting results [19–27]. Most of such studies 
included an unselected population with an unknown EGFR 
status, showing no significant differences between the two 
treatment arms in all patients’ outcomes [28]. However 
also the results of the studies performed in EGFR wild-
type (WT) patients are controversial [29, 30],  suggesting a 
potential survival benefit in favor of chemotherapy [31], but 
highlighting the urgent need of direct comparisons between 
TKI and chemotherapy in this setting of NSCLC patients. 
We compared clinical outcomes of erlotinib and of single-
agent chemotherapy in EGFR-WT or unknown NSCLC 
patients who progressed to first-line platinum-chemotherapy.
In EGFR wild-type NSCLC the EGFR pathway is 
activated, even though the excessive activity of kinase 
domain as in the mutant EGFR receptor lacks. This 
explains why EGFR driver mutations have an oncogenic 
effect. The modestly activated non-mutated EGFR has 
anyways a role in cancer promotion by the induction of 
cell proliferation, apoptosis inhibition, angiogenesis, 
cellular motility and invasiveness [32].
The aim of this study was to demonstrate the best 
second-line treatment option in a real-life EGFR-WT or 
unknown NSCLC population, trying to identify a preferred 
sequence of treatment, considering at least two or three 
lines of therapy and alternating respectively chemotherapy 
and TKI. The results could help to understand the role of 
EGFR-TKI in the sequence strategy. This information 
could help decision making in light of the new options for 
second-line treatment in EGFR-WT patients.
RESULTS
Patients characteristics
93 patients have met the criteria and have been 
selected for the first evaluation. 69 were male while 
24 female and the mean age at diagnosis was 66,7 (range 
46–84). 39 EGFR-WT and 54 EGFR-UK. All patients 
received a first-line chemotherapy and a TKI as second- 
or third-line treatment: 80 among them were treated 
with a platinum-based doublet chemotherapy, while 13 
with single-agent chemotherapy. All patients received at 
least one line of EGFR-TKI: 67 as second-line and 26 
as third-line treatment after second-line chemotherapy. 
Table 3 and Figure 3 summarize the main characteristics 
of the 93 cases analyzed. Among patients treated with 
TKI as second-line treatment, 13 received gefitinib and 
54 erlotinib. Among patients treated with TKI as third-
line treatment all received erlotinib. The following 
analyses were conducted comparing two defined groups 
of patients: patients treated in sequence with two lines of 
chemotherapy followed by TKI in the third (CT-CT-TKI) 
and patients treated with first-line chemotherapy, TKI in 
second and subsequent third-line chemotherapy (CT-TKI-
CT). We evaluated TTP of the second-line and the third-
line treatment, and OS. For the comparison of these main 
endpoints (TTP and OS) for the second-line treatment, we 
included data even from patients treated with only two 
lines of treatment (CT-TKI).
TTP of second- and third-line treatment  
(TKI vs CT)
No statistically significant difference was found, in 
terms of TTP, for EGFR-WT or EGFR-UK patients treated 
with TKI or chemotherapy as second-line treatment: 
mTTP 5 vs 4 months; HR: 0,91 (TKI vs  CT) 95% CI: 
0,57–1,45; p = 0,6333 (Figure 1). Similarly, the analysis of 
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Table 1: Baseline patients’ characteristics
Characteristics N  (%)
Mean age at diagnosis  (range)
< 65
≥ 65
66,7 (46–84)
34 (36,6)
59 (63,4)
Sex
M
F
69 (74,2)
24 (25,8)
Performance status
0–1
2
86 (92,5)
7 (7,5)
Smoking status
Yes
No
Former
42 (45,2)
18 (19,3)
33 (35,5)
Histology
Squamous
Adenocarcinoma
Other
24 (25,8)
56 (60,2)
13 (14,0)
Stage at diagnosis
I–IIIA
IIIB–IV
9 (9,7)
84 (90,3)
Comorbidity
Yes
No
56 (60,2)
37 (39,8)
Number of metastatic sites
1
2
≥ 3
32 (34,4)
37 (39,8)
24 (25,8)
EGFR
Wild-type (WT)
Unknown (UK)
39 (41,9)
54 (58,1)
Figure 1: Survival curves of TTP for second-line treatment (TKI vs CT).
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the TTP of the third-line treatment confirms the substantial 
overlap of the two strategies (TKI and CT): mTTP 2 vs 
3 months; HR: 1.1; (TKI vs CT); 95% CI: 0.62 to 1,97; 
p = 0,6951. Even in this graph, the curves representing 
the two treatments under comparison are almost identical, 
although a fewer number of patients continue to benefit, to 
date, by such therapies (Figure 2). The Table 2 summarizes 
these data.
Overall survival
For OS analysis we compared EGFR-WT and 
EGFR-UK patients treated with TKI as second- (CT-TKI) 
or third-line therapy (CT-CT-TKI) respectively. The results 
showed a trend toward a benefit for patients in the third-
line TKI group: mOS 26 vs 15 months (third-line TKI vs 
second-line TKI), HR: 0,68, 95% CI: 0,42–1,09; p = 0,11. 
No statistical significance have been found (Figure 3). 
Among patients treated with TKI as second-line treatment, 
a consistent number of them (N = 40) were treated only 
for two lines of therapy, showing lower survival (Table 3). 
However in the survival comparison between patients 
who have been treated with at least three lines of therapy 
(CT-CT-TKI vs CT-CT-TKI), a statistically non-significant 
trend has been also confirmed in favor of the TKI in the 
third-line treatment (mOS 26 vs 18 months; HR: 0,7; 
p = 0,21) (Figure 4 and Table 3).
DISCUSSION
This retrospective analysis has been carried out in 
order to find confirmation of the rationale of EGFR-TKI 
use for EGFR-WT and EGFR-UK NSCLC patients in 
every day clinical practice. Although the best outcomes 
are obtained from the use of TKIs as upfront treatment 
in EGFR mutated patients, all the international guidelines 
agree to recommend erlotinib as potential treatment option 
even for EGFR-WT patients who progressed to first-line 
platinum-chemotherapy [33]. Indeed a modest activation 
of  the EGFR signaling pathway has been demonstrated 
also in EGFR-WT NSCLC, promoting cancer cells 
proliferation, motility and invasiveness, stimulating 
tumor angiogenesis and inhibiting apoptosis processes 
[32, 34]. Additionally several phase II studies have shown 
encouraging activity and survival outcomes of erlotinib as 
second/third-line treatment in EGFR-WT NSCLC patients 
[35–37], whereas the randomized phase III BR.21 study 
demonstrated a significant benefit of erlotinib over placebo 
in a pre-treated and unselected NSCLC population [18], 
leading to its approval in such setting in 2004. A real-word 
cost-effectiveness analysis was conducted in NSCLC 
patients who received erlotinib after prior chemotherapy-
regimens, suggesting it as a cost-effective treatment in this 
setting of patients [38]. However it has not been clarified 
yet the best allocation of EGFR-TKI (second- or third-line 
setting) in the treatment strategy of such patients.
This study was intended for the assessment of the 
efficacy of EGFR-TKIs (erlotinib or gefitinib) compared 
to standard single-agent chemotherapy (docetaxel or 
pemetrexed) as second- or third-line treatment in EGFR-
WT/UK NSCLC population. The aim was the finding of 
support to identify a preferred sequence of treatment for 
these patients. Overall the baseline patients’ characteristics 
in the present study were similar to those reported in 
other prospective randomized studies, including the high 
percentage of both adenocarcinoma histology and good 
Figure 2: Survival curves of TTP for third-line treatment (TKI vs CT).
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PS [18, 25, 39].  The results of our analyses showed the 
substantial equality in terms of TTP of the two treatment 
strategies (TKI vs CT) both in second- and in third-line 
setting. Such data are opposite to the results from the most 
recent published randomized trials, including TAILOR, 
CTONG0806 and DELTA studies [25–27]. All of these ones 
show a significant superior PFS in favor of chemotherapy 
over TKI in EGFR-WT NSCLC patients who progressed 
to first-line treatment. Such discordance could be explained 
by the high percentage (58%) of patients with an unknown 
EGFR mutational status included in our study.  Another 
possible explanation may entail the lower sensitivity of the 
techniques used for the assessment of EGFR mutational 
status in our study, compared to the advanced platforms 
with higher sensitivity used in more recent trials (i.e. Sanger 
Sequencing vs Next-Generation Sequencing, respectively). 
As regards the OS analysis, our results suggest that 
treatment with EGFR-TKI is not inferior to the standard 
single-agent chemotherapy. Trends toward better OS were 
observed with third-line EGFR-TKI in both the comparisons 
(CT-TKI vs CT-CT-TKI and CT-TKI-CT vs CT-CT-TKI), 
although such differences were not statistically significant. 
According to other recently published randomized trials 
[25, 26], such evidences suggest a potential superiority 
of second-line chemotherapy over EGFR-TKI in NSCLC 
patients with EGFR-WT/UK, which failed to reach a 
Table 2: TTP of second- and third-line treatment (TKI vs CT)
TKI CT
HR 95% CI P
mTTP (months) N mTTP (months) N
Second line 5 58 4 26 0,91 0,57–1,45 0,6333
Third line 2 22 3 25 1,1 0,62–1,97 0,6951
Table 3: Overall survival according to TKI position (3rd-line vs 2nd-line) and overall sequence 
(CT-CT-TKI vs CT-TKI-CT)
Treatment mOS(months) N HR 95% CI P
TK
I 
po
si
tio
n 3rd-line TKI 26 22
0,68 0,42 – 1,09 0,11
2nd-line TKI 15 51
O
ve
ra
ll 
se
qu
en
ce CT-CT-TKI 26 21
0,70 0,39 – 1,24 0,21
CT-TKI-CT 18 26
Figure 3: Survival curves of OS for the comparison 3rd-line vs 2nd-line TKI.
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statistical significance because of the effect of the treatment 
cross-over on the outcomes. Furthermore we can affirm 
that the potential OS benefit in favor of second-line CT 
is not induced by the number of treatment lines, but it’s 
likely related to the right sequence of drugs. Anyway the 
significance of results in a retrospective analysis remains 
uncertain. Indeed as a retrospective study, our work has 
several limitations, primarily the small number of subjects 
included as well as the high percentage of patients with an 
unknown EGFR mutation status, which of course reduce 
the reliability of our data. Analyzing our results we can 
conclude that, as recommended by all the international 
guidelines, both chemotherapy and EGFR-TKI are equal 
treatment options for NSCLC patients who progressed 
to first-line platinum-based chemotherapy. However 
for those patients with good PS who are fit to receive it, 
chemotherapy could represent the preferred second-line 
option, reserving EGFR-TKI as third-line therapy. Similarly 
EGFR-TKI, thanks to its peculiar tolerability profile can 
be considered as a valid alternative to chemotherapy for 
those patients with a poor PS or other comorbidities, who 
are unable to tolerate single-agent chemotherapy but are 
eligible for a second-line treatment. Moreover the LUX-
Lung 8 trial compared afatinib with erlotinib, as second-line 
treatment for patients with advanced squamous NSCLC. 
PFS and OS were improved by afatinib. So this irreversible 
EGFR-TKI should be considered as an alternative option in 
this setting [40].
Recently several studies investigated the potential 
role of a “proteomic scoring” by mass spectrometry 
analysis of serum to identify EGFR-WT patients most 
likely to benefit from EGFR-TKI [41–43]. Recently a 
phase III randomized study has shown that patients with 
a “poor proteomic score” had inferior OS with EGFR-TKI 
compared to chemotherapy [44]. Other studies evaluated 
germline genetic polymorphisms as predictors of response 
to EGFR-TKIs, showing that genetic polymorphisms of 
EGFR and downstream PI3K/AKT signaling pathways 
may be surrogate biomarkers of EGFR-TKI activity and 
toxicity in NSCLC patients [45–48]. Such data suggest that 
there is a high inter-patient variability likely related to their 
pharmacogenetic heterogeneity. However such findings 
have not been translated into clinical practice yet. Therefore 
clinical criteria, including patient’s age, PS, comorbidities 
and toxicities, remain still crucial in the choice of the best 
second-line treatment, which should be individualized 
according to every patient’s characteristics and preferences.
CONCLUSIONS
This study, far to draw any definitive conclusions, is a 
report of real-life clinical practice, which aims to stimulate 
the current open debate on the best treatment algorithm 
in EGFR-WT NSCLC patients, highlighting the urgent 
need for further studies on this topic. EGFR-TKI should 
be considered as a treatment option after progression upon 
progression to first-line treatment. Probably the advent of 
new drugs recently approved in second-line setting will 
lead to new treatment algorithms, but it is still far from 
clinical practice. In this framework this study could support 
the use of EGFR-TKI as third-line treatment option after 
new second-line treatment regimens. 
Figure 4: Survival curves of OS for the comparison CT-CT-TKI vs CT-TKI-CT.
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MATERIALS AND METHODS
Objectives of the study
Primary objective of the study has been to determine 
what is the most appropriate treatment between TKI and 
chemotherapy in EGFR-WT (ascertained non-mutated 
EGFR status) or EGFR-UK (unknown EGFR mutational 
status) advanced NSCLC patients, after progression from a 
first-line chemotherapy. The two second-line options would 
be compared on the basis of efficacy data: time to progression 
(TTP) and overall survival (OS). The same comparison 
would be also carried out for the third-line treatment.
Secondary objective of the study was to evaluate 
the influence of activity and effectiveness of the first-line 
chemotherapy, and the activity and effectiveness of TKI as 
second-line treatment. To address this objective we would 
analyze the association between the first-line chemotherapy 
responders and responders to the second-line treatment 
with TKI. As “responders” we mean those patients that 
have shown complete (CR), partial response (PR) or stable 
disease (SD) lasting six months or more. Conversely “non-
responders” are those patients who have shown progressive 
disease (PD) or SD ≤ 6 months. In addition, we would 
evaluate the influence of the TTP to first-line chemotherapy 
on the TTP to second-line treatment with TKI.
Study design
This study was carried out as a retrospective 
analysis by data collected from medical records of 
patients with histologically confirmed diagnosis of locally 
advanced or metastatic (Stage IIIB–IV) NSCLC and 
treated  for at least two lines of therapy and at least one 
line of EGFR-TKI. We evaluated patients treated from 
2005 to present in various cancer centers in Italy. Patients 
with EGFR mutations were excluded and we selected 
for the analysis only EGFR-WT and EGFR-UK patients 
evaluating the second- and third-line treatment, after first-
line chemotherapy.
Eligibility criteria
The patients were included for the analysis if they 
met the following eligibility criteria.
Inclusion criteria:
•  Histologically confirmed diagnosis of stage 
IIIB– IV NSCLC;
•  History of at least two lines of treatment for the 
advanced disease, with at least an instrumental 
re-evaluation of the disease after at least two 
months for each line of treatment;
•  History of at least one line of treatment with a 
TKI.
Exclusion criteria:
• Early stage NSCLC;
• EGFR mutated status;
• Treatment with TKI after the third-line treatment;
•  Interruption of any of the treatments before two 
months from the beginning.
Data collection
Data would be collected from paper or electronic 
databases after the obtainment of written informed consent 
to cancer treatment and processing of personal data. The 
following characteristics were evaluated for every single 
patient.
Patient’s data: 1) sex; 2) age at diagnosis; 3) smoking 
status; 4) Eastern Cooperative Oncology Group Performance 
Status (ECOG PS) at diagnosis; 5) Comorbidities. Disease’s 
data: 1) histotype; 2) stage at diagnosis  (IIIB or IV); 3) 
sites of metastases; 4) EGFR mutational status (EGFR-WT 
or EGFR-UK); 5) type of EGFR mutation. Treatments and 
outcomes: 1) type of treatment (schedules and drugs); 2) 
best objective responses (complete response (CR), partial 
response (PR), stable disease (SD), progressive disease 
(PD), according to  RECIST criteria); time-to-progression 
(TTP), meant as the time in months from the beginning of 
any treatment and progression; overall survival (OS) meant 
as the time in months from the beginning of the treatments 
and death or the last visit.
Statistical analysis
The analyses were performed by MedCalc version 
14.12.0. For the comparison of the effectiveness of CT 
and TKI at second- and third-line for TTP and OS, we 
performed the Kaplan-Meyer test with use of the log-
rank test to calculate median TTP (mTTP) and median 
OS (mOS). For all statistical tests, a p < 0.05 has been 
considered as statistically significant.
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